SCHEMBL26359486

SCHEMBL26359486

COCCOC1OC(CO)C(O)C(OCCOP(C)(=O)O)C1NC(C)=O

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.50
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
LGALS3 P17931 4/20 0.46
LGALS8 O00214 1/20 0.46
LGALS4 P56470 1/20 0.46
ALDH1A1 P00352 2/20 0.42
THRB P10828 1/20 0.42
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
CD69 Q07108 1/20 0.39
LGALS1 P09382 1/20 0.39
LGALS7; LGALS7B P47929 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
POLB P06746 1/20 0.38
B4GALT1 P15291 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26359484 0.89 MAPK1 (0.52) MAPK1MEN1KMT2ALGALS3LGALS8
SCHEMBL26359482 0.84 LGALS8 (0.40) LGALS3LGALS8
SCHEMBL26359459 0.83 MAPK1 (0.52) MAPK1MEN1KMT2ALGALS3LGALS8
SCHEMBL24725001 0.81 MAPK1 (0.71) MAPK1MEN1KMT2ALGALS3LGALS8
SCHEMBL26359490 0.81 IGF2R (0.39) LGALS8CA1CA2CA9
SCHEMBL26031843 0.81 MAPK1 (0.46) MAPK1MEN1KMT2ALGALS3LGALS8
SCHEMBL26359436 0.80 MAPK1 (0.51) MAPK1MEN1KMT2ALGALS3LGALS8
SCHEMBL26359458 0.79 IGF2R (0.43) LGALS3LGALS8LGALS4
SCHEMBL2365088 0.78 MAPK1 (0.80) MAPK1MEN1KMT2ALGALS3LGALS8
SCHEMBL4964501 0.77 MAPK1 (0.48) MAPK1MEN1KMT2ALGALS3LGALS8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230304002-A1 TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES BANK OF AMERICA, N.A. 2023-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230304002-A1 TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES TTR, MTPN, CRYAA MAPK1 4621/4885MEN1 3220/4885KMT2A 4228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.